Drug intelligence / Profile preview

canagliflozin + phentermine

Development stage: Unknown
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy that pairs canagliflozin, an SGLT2 inhibitor, with phentermine, a sympathomimetic amine anorectic. Canagliflozin works by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and caloric loss. Phentermine acts by stimulating satiety centers in the brain through increased levels of norepinephrine, dopamine, and serotonin. The combination produced meaningful weight loss in clinical trials with overweight or obese individuals without type 2 diabetes.

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)SGLT2 (Sodium-glucose cotransporter protein subunit 2)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on canagliflozin + phentermine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on canagliflozin + phentermine.

Explore the full profile